Mall PA
TESA NOT FOR HUMANS BANNED IN TESTED SPORT
File 08 · synthetic GHRH analog (44 amino acids); FDA-approved prescription drug

Tesamorelin

Also called: Egrifta, Egrifta SV, Egrifta WR, TH9507

Banned · S2Approved drug (for a different use)

Tesamorelin is a stabilized version of the full 44-amino-acid growth hormone-releasing hormone. It is FDA-approved (as Egrifta) to reduce excess abdominal visceral fat in adults with HIV who have lipodystrophy.

Why the gym talks about it

Because it is an approved drug with solid trial data on visceral (belly) fat, it has a reputation as the 'legit' GH-releasing peptide for cutting and recomposition. The trial data, however, come from people with HIV lipodystrophy, not lifters.

What the research actually found

  • approved drug data (phase 3, HIV lipodystrophy)In a 26-week randomized trial of 412 people with HIV and abdominal fat buildup, tesamorelin cut visceral fat by 15.2% versus a 5.0% increase on placebo, raised IGF-1 by 81% and improved triglycerides. Source
  • randomized human trial (HIV-associated NAFLD)In people with HIV and fatty liver disease, tesamorelin reduced liver fat versus placebo in a randomized trial. Source
  • approved drugFDA approved a new formulation, Egrifta WR (tesamorelin F8), on March 25, 2025 for the same HIV visceral-fat indication. Source

Human evidence: approved drug (for a different use). Strong randomized data in adults with HIV-associated lipodystrophy; there are no trials in healthy lifters for physique or performance.

Tested lifters

S2.2.4 GHRH and its analogues. Tesamorelin is named; prohibited at all times.

High without a Therapeutic Use Exemption. Being an approved drug does not exempt it. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

FDA-approved prescription drug: Egrifta (2010), with the Egrifta WR formulation approved March 25, 2025, indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. Any other use is off-label. Gray-market 'research' tesamorelin is not an approved product.

As of 2026-10-01.

Known and theoretical risks

  • Label contraindications include active malignancy, disruption of the hypothalamic-pituitary axis, hypersensitivity and pregnancy. Source
  • Label warnings: raised IGF-1 (long-term effects unknown), fluid retention (swelling, joint pain, carpal tunnel), glucose intolerance or diabetes, hypersensitivity reactions (about 4% in trials) and injection-site reactions. Source
  • Most common adverse reactions in trials: joint pain, injection-site redness and itching, limb pain, peripheral swelling and muscle pain. Source

Quick answers

Is Tesamorelin banned for drug-tested lifters?

S2.2.4 GHRH and its analogues. Tesamorelin is named; prohibited at all times. High without a Therapeutic Use Exemption. Being an approved drug does not exempt it. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is Tesamorelin FDA approved?

FDA-approved prescription drug: Egrifta (2010), with the Egrifta WR formulation approved March 25, 2025, indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. Any other use is off-label. Gray-market 'research' tesamorelin is not an approved product.

How strong is the human evidence for Tesamorelin?

Approved drug (for a different use). Strong randomized data in adults with HIV-associated lipodystrophy; there are no trials in healthy lifters for physique or performance.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement